Compare Elder Pharma with Dishman Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DISHMAN PHARMA - Comparison Results

DISHMAN PHARMA 
   Change

Dishman Pharmaceuticals is involved in the manufacture of APIs (active pharmaceutical ingredients), intermediates, quaternary compounds and fine chemicals. Besides this, the company is a significant player in the CRAMS (Contract Research and Manufact... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DISHMAN PHARMA ELDER PHARMA/
DISHMAN PHARMA
 
P/E (TTM) x -0.2 25.1 - View Chart
P/BV x 0.1 3.3 3.0% View Chart
Dividend Yield % 0.0 0.7 -  

Financials

 ELDER PHARMA   DISHMAN PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DISHMAN PHARMA
Mar-16
ELDER PHARMA/
DISHMAN PHARMA
5-Yr Chart
Click to enlarge
High Rs380374 101.5%   
Low Rs188129 145.8%   
Sales per share (Unadj.) Rs491.2197.8 248.3%  
Earnings per share (Unadj.) Rs-3.221.2 -15.0%  
Cash flow per share (Unadj.) Rs14.434.7 41.5%  
Dividends per share (Unadj.) Rs02.00 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs376.5179.9 209.3%  
Shares outstanding (eoy) m20.5480.69 25.5%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.61.3 45.4%   
Avg P/E ratio x-89.311.9 -752.2%  
P/CF ratio (eoy) x19.77.2 272.0%  
Price / Book Value ratio x0.81.4 53.9%  
Dividend payout %09.4 0.0%   
Avg Mkt Cap Rs m5,83320,306 28.7%   
No. of employees `000NA0.8 0.0%   
Total wages/salary Rs m2,1795,355 40.7%   
Avg. sales/employee Rs ThNM19,252.7-  
Avg. wages/employee Rs ThNM6,459.5-  
Avg. net profit/employee Rs ThNM2,064.1-  
INCOME DATA
Net Sales Rs m10,08915,961 63.2%  
Other income Rs m257265 96.7%   
Total revenues Rs m10,34616,226 63.8%   
Gross profit Rs m-7924,103 -19.3%  
Depreciation Rs m3611,091 33.1%   
Interest Rs m2,756944 291.9%   
Profit before tax Rs m-3,6532,334 -156.5%   
Minority Interest Rs m00-   
Prior Period Items Rs m01 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m125624 20.1%   
Profit after tax Rs m-651,711 -3.8%  
Gross profit margin %-7.825.7 -30.5%  
Effective tax rate %-3.426.7 -12.8%   
Net profit margin %-0.610.7 -6.0%  
BALANCE SHEET DATA
Current assets Rs m9,24011,018 83.9%   
Current liabilities Rs m9,9989,517 105.1%   
Net working cap to sales %-7.59.4 -79.9%  
Current ratio x0.91.2 79.8%  
Inventory Days Days46110 41.9%  
Debtors Days Days6035 172.1%  
Net fixed assets Rs m10,12416,304 62.1%   
Share capital Rs m206161 127.4%   
"Free" reserves Rs m5,58212,907 43.3%   
Net worth Rs m7,73414,516 53.3%   
Long term debt Rs m4,8894,189 116.7%   
Total assets Rs m22,88229,805 76.8%  
Interest coverage x-0.33.5 -9.4%   
Debt to equity ratio x0.60.3 219.0%  
Sales to assets ratio x0.40.5 82.3%   
Return on assets %11.88.9 132.0%  
Return on equity %-0.811.8 -7.2%  
Return on capital %22.317.5 127.3%  
Exports to sales %3.024.8 12.3%   
Imports to sales %0.43.7 11.4%   
Exports (fob) Rs m3073,956 7.7%   
Imports (cif) Rs m43596 7.2%   
Fx inflow Rs m3074,952 6.2%   
Fx outflow Rs m125697 18.0%   
Net fx Rs m1814,255 4.3%   
CASH FLOW
From Operations Rs m11,7542,786 421.8%  
From Investments Rs m-561-1,529 36.7%  
From Financial Activity Rs m-6,762-941 718.5%  
Net Cashflow Rs m4,432316 1,400.7%  

Share Holding

Indian Promoters % 39.6 61.4 64.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 3.7 202.7%  
FIIs % 16.8 12.7 132.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 22.1 163.3%  
Shareholders   16,479 46,261 35.6%  
Pledged promoter(s) holding % 77.6 35.8 216.9%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   PANACEA BIOTECH  BIOCON   FULFORD INDIA  NATCO PHARMA  DIVIS LABORATORIES  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Continue Downtrend, Developments From the IPO Space, and Top Cues in Focus Today(Pre-Open)

On Tuesday, Indian share markets fell sharply during closing hours amid fears of rising crude oil prices and weakness in the rupee.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

A Recession Proof Stock You Can Bet On(Profit Hunter)

Sep 10, 2019

Usually, the typical horizon period for my smallcap recommendations is 3 to 5 years. But if you ask me, this could be one business that you could own and pass on to future generations.

This Company Will Do Well Despite the Slowdown(The 5 Minute Wrapup)

Sep 11, 2019

How financial inclusion provides a big runway for this stock recommendation.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS